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ABSTRACT: In the recent years, organometallic compounds have become recognized as 
promising anti-cancer drug candidates. While radioactive 186/188Re compounds are already used in 
clinics for cancer treatment, cold Re organometallic compounds have mostly been explored as 
luminescent probes and photosensitizers in photo-catalysis. However, a growing number of 
studies have recently revealed the potential of Re organometallic complexes as anticancer agents. 
Several compounds have displayed cytotoxicity equaling or exceeding that of the well-established 
anti-cancer drug cisplatin. In this review, we present the currently known Re organometallic 
complexes that have shown anti-proliferative activity on cancer cell lines. A particular emphasis 
is placed on their cellular uptake and localization as well as their potential mechanism of action. 
 
INTRODUCTION 
Despite the growing body of research, cancer remains among the leading causes of death in the 
world, in particular in high-income countries (although cancer rates are increasing in lower-
income countries which already account for 70% of world cancer deaths).1 The survival rates 
hugely vary with the type and stage of tumor, as well as age, sex and socio-economic situation 
of each patient.1, 2 For example, about 50% of adult (15-99 years old) patients diagnosed with 
cancer in England and Wales in 2010-2011 are expected to survive for another 10 years or more.2 
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However, while patients with testicular cancer, melanoma, prostate cancer and Hodgkin 
lymphoma have a ten-year survival rate of over 80%, less than 15% of patients with pancreas, 
lung, brain, esophagus and stomach cancers survive that long.2 Cancer treatment depends on the 
type, stage and location of tumor, but most patients undergo chemotherapy either as the main 
treatment or in combination with surgery and/or radiotherapy. Over 50% of tumors are treated 
with platinum-based drugs (cisplatin, carboplatin, oxaliplatin) alone or co-administered with 
other chemotherapeutic agents.3 Nevertheless, new anti-cancer drugs are still being actively 
sought due to the emergence of platinium resistance and the severe side effects associated with 
the chemotherapic treatments.4 In the last decades, many organometallic compounds (i.e. 
compounds containing at least one metal-carbon bond) have proven themselves as extremely 
promising anti-cancer drug candidates.5-14 Organometallic complexes offer structural and 
stereochemical variety,15, 16 the possibility of rational ligand design, and diverse mechanisms of 
action (e.g. via redox activity, ligand exchange, catalytic activity and/or photo-activity).17 18-21  
Compared with some intensively investigated organometallic complexes such as those based 
on ruthenium,12, 13 relatively few examples of cytotoxic rhenium organometallic compounds are 
found in the literature. However, numerous studies have been recently reported describing the 
potential of such compounds.22-47 Indeed, Re organometallic compounds possess several 
intrinsic properties advantageous for the development of novel anti-cancer drug candidates. For 
instance, many Re organometallic complexes are excellent luminescent probes with long-lived 
emission states, large Stokes shifts, high quantum yields and emission that can be tuned by 
varying the ligands.37, 48 They can thus be easily followed inside cells by conventional and/or 
time-resolved (e.g. FLIMS) emission microscopy to elucidate their cellular distribution and 
mechanism of action. Furthermore, all reported cytotoxic Re organometallic compounds are 
based on the Re(CO)3 core, which is chemically robust and easily accessible, e.g. from 
[Re(CO)3(H2O)3]+/[ReBr3(CO)3]2-,29, 34 Re(CO)5Cl/Re(CO)5Br26-28, 31-33, 41, 42, 49 or Re2(CO)1024, 30, 
40 in 1-3 step synthesis. The introduced ligands can be designed to incorporate other functional 
moieties such as targeting biomolecules.28, 29, 34, 35, 39, 41, 44, 46, 47, 50, 51 However, the key property of 
the Re organometallic complexes is the possibility to prepare “hot” analogues that can be applied 
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for radio-imaging as well as for therapy. Besides 186Re and 188Re isotopes, 99mTc can often be 
used with the same set of ligands as the cold Re due to the similarity in the coordination 
chemistry of these group 7 congeners.52-55 Thus, a Re complex has the potential to be a multi-
modal molecule, which acts as a luminescent probe, a radio-imaging and a pharmaceutical agent. 
Importantly, “hot” analogues can be used to run in vivo biodistribution and pharmacokinetics 
studies, which are crucial for the development of new drugs.  
In this review, we present the cytotoxic Re organometallic complexes that have been reported 
in the literature to date. Their modes of cytotoxic action, when known, are discussed in detail. 
The compounds presented in this review are categorized into two main groups according to the 
nature of their anti-proliferative activity, namely “traditional” cytotoxicity and photo-toxicity. 
Anti-cancer and other therapeutic applications of radio-pharmaceuticals based on 186/188Re have 
been extensively described in several excellent reviews.54, 56-59 Since some of them are extremely 
recent, this topic is not discussed herein. Of note, two relatively recent and comprehensive 
reviews by Lo et al.37 and Coogan et al.48 have discussed the cellular uptake, localization and 
cytotoxicity of luminescent Re(I) organometallic complexes, but both are more focused on 
imaging applications and do not cover non luminescent organometallic Re compounds. As can 
been seen in these reviews, several Re complexes have been reported to interact with DNA 
and/or proteins, yet not all of them have been screened for cytotoxicity. Here we discuss only 
the Re organometallic compounds that have been studied in cell culture. 
CYTOTOXIC Re ORGANOMETALLIC COMPLEXES 
Re(I) tricarbonyl bisimine complexes. A large percentage of cytotoxic Re organometallic 
compounds have been initially developed as luminescent probes and their anti-cancer effect has 
only been discovered during biocompatibility screenings. Unsurprisingly, the largest family of 
anti-proliferative Re organometallic compounds is that of [2+1] Re(I) tricarbonyl bisimine 
complexes [Re(CO)3(bisimine)L] where L is a monodentate pyridine derivative or a halide (Cl, 
Br) ligand. These compounds normally possess outstanding photochemical properties and their 
bisimine or pyridine ligands can be easily derivatized. Typically used bisimine ligands are 2,2’-
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bipyridine or phenantroline-based (Figure 1) and, despite apparent similarity, cytotoxicity varies 
considerably from one derivative to another. 
The cytotoxicity of several bipyridine and phenantroline based Re(I) complexes (Figure 1A 
and B, 1-14) have been reported. Their anti-proliferative activity reached or even exceeded the 
one of cisplatin on various human cancer cell lines.28, 30, 32, 39, 40, 45, 49, 51 The cytotoxicity of the 
compounds generally increased with lipophilicity,32, 33, 39, 49, 51 most probably due to an improved 
cellular uptake. Re(I) complexes 9 (Figure 1A) derivatized with a fluorous pendant were the 
only exception to this trend. Their cytotoxicity diminished with rising lipophilicity.39  
However, these compounds are exceptionally lipophilic (logPo/w in the range of 5 to 9) and 
could form self-aggregates due to favorable F-F interactions. The uptake of anti-proliferative 
Re(I) tricarbonyl bisimine complexes is often very fast and efficient, yet little is known about 
their mechanism. Some cytotoxic cationic complexes such as 1a-c appear to accumulate in cells 
via passive diffusion.49 Re luminescent probes used to sense Cd(II) and Zn(II) (5 on Figure 1A) 
are, however, taken up via an energy-dependent pathway such as endocytosis as demonstrated 
by temperature and ATP production inhibition uptake assays.32 Interestingly, fluorescence 
microscopy cellular localization studies have never – to the best of our knowledge – identified a 
cytotoxic Re(I) tricarbonyl bisimine complex located inside the nucleus. All compounds 
screened for cytotoxicity were indeed imaged in the cytoplasm.28, 32, 33, 39, 51 When co-localization 
experiments were performed on Re organometallic complexes 7i and 9f (Figure 1A), 
predominately mitochondrial (up to 80%) localization was reported.39 A non-negligible 
percentage of endosomal accumulation (about 20%) has also been detected for compound 7i39 
As a note of caution, although fluorescent microscopy imaging is an important tool in the 
investigation of the cellular behavior of Re organometallic complexes, their luminescence can 
sometimes be quenched in cells.39, 44, 47 Due to this problem, direct measurements of Re content 
by inductively coupled plasma mass spectrometry (ICP-MS) or atomic absorption spectroscopy 
(AAS)60 can be a more accurate method to quantify the cellular uptake and distribution of Re 
complexes. 
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The first cytotoxic bisimine Re complex (15 on Figure 1B) with anti-proliferative properties, 
however, was in some ways an exception to the typical photo-physical and biological properties 
of these compounds. Based on a pyridine-triazine ligand (2-amino-4-phenylamino-6-(2-
pyridyl)-1,3,5-triazine), compound 15 emitted only in the solid state and was designed in a 
crescent shape to fit the major or minor grooves of DNA.27 Experimental evaluation of its 
interactions with DNA has indeed demonstrated that 15 was non-intercalatively binding to DNA 
with a preference for AT-rich sequences. Modeling studies suggested the minor groove as 
binding site. The resulting cytotoxicity was only moderate (IC50 of 30-50 M compared with 
10-20 M IC50 for cisplatin) on KB-3-1 (human epidermoid carcinoma), HepG2 (human liver 
hepatocellular carcinoma) and HeLa (human cervical cancer) and low (195 M compared with 
40 M for cisplatin) on human multi-drug resistant epidermal carcinoma KB-V-1 cell line. Since 
the compound was not fluorescent in solution, its localization in cell could not be determined by 
fluorescence microscopy. Therefore it is unknown whether it reaches cell nucleus or/and 
mitochondria where it could interact with DNA.  
Another Re(I) tricarbonyl diimine compound using neither bipyridine nor phenathroline, but 
asymmetric azines (16 on Figure 1B) as bidentate ligands have been reported to be active on 
human neuroblastoma NB69, glioblastoma astrocytoma U373, breast cancer MRC-7 (hormone-
responsive) and EVSA-T (hormone-independent) with IC50 in the 4–10 M range.31 Some azines 
are known to possess some anti-cancer activity on their own, but their cytotoxicity was increased 
by coordination to the Re center. Curiously, Re(CO)5Cl displayed the same activity as Re(I) 
azines, while Re(CO)5Br failed to produce a strong anti-proliferative effect on U2OS 
(osteosarcoma, >100 M), HepG2 (>100 M) and MCF-7 (57 M) in a different study.44 
Although a substantial number of Re(I) tricarbonyl bisimine complexes 
[Re(CO)3(bisimine)L] have been reported, their mechanism of cytotoxicity has not yet been fully 
elucidated. In particular, studies on the compounds’ stability in biological conditions (e.g. in 
blood plasma) are lacking. Evaluation of [Re(CO)3(bisimine)L] complexes’ stability could shed 
some light on their behavior in cells, since, for some of these compounds, the monodentate ligand 
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can be easily substituted51, 61-64 or modified40 under physiological conditions. For instance, the 
monodentate pyridine ligand can sometimes be substituted by stronger donor groups (e.g. 
histidine or cysteine),61 while alkylcarbonato ligands (compounds 11 and 12 on Figure 1B) are 
transformed into alkyloxo via CO2 loss in cell culture medium.40 In fact, [2+1] 99mTc tricarbonyl 
pyridine-based complexes have also been prepared, but have not been extensively developed 
due to concerns about their stability.61-63 
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Figure 1A. Cytotoxic Re(I) tricarbonyl bisimine complexes. 
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Figure 1B. Cytotoxic Re(I) tricarbonyl bisimine complexes (continued).  
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Table 1. Cytotoxicity of Re organometallic compounds towards human cancer cell lines. 
Compound IC50 (M) Known druga 
IC50 (M) 
Cell line Incubation 
time 
Reference 
3a 22.7 26.7  HeLa 48 h 28 
3b 17.5 26.7 HeLa 48 h 28 
3c 28.5 26.7 HeLa 48 h 28 
5a 4.0 ± 0.5 19 ± 0.4  HeLa 48 h 32 
5b 2.3 ± 0.2 19 ± 0.4 HeLa 48 h 32 
5c 0.7 ± 0.1 19 ± 0.4 HeLa 48 h 32 
6a 7.7 ± 1.0 25.6 ± 2.3  HeLa 48 h 33 
7a 26.0 ± 1.6 11.9 ± 0.3 HeLa 48 h 39 
7d 15.0 ± 4.8 11.9 ± 0.3 HeLa 48 h 39 
7e 11.9 ± 1.6 11.9 ± 0.3 HeLa 48 h 39 
7h 5.0 ± 0.4 11.9 ± 0.3 HeLa 48 h 39 
7i 6.6 ± 0.4 11.9 ± 0.3 HeLa 48 h 39 
7l 3.6 ± 0.4 11.9 ± 0.3 HeLa 48 h 39 
8a >1151.7 11.9 ± 0.3 HeLa 48 h 39 
8d 159.1 ± 8.0 11.9 ± 0.3 HeLa 48 h 39 
9a 4.01 ± 0.14 34.0 ± 3.3 HeLa 48 h 65 
9b 6.10 ± 0.37 34.0 ± 3.3 HeLa 48 h 65 
9c 10.7 ± 0.53 34.0 ± 3.3 HeLa 48 h 65 
9g 12.9 ± 0.23 34.0 ± 3.3 HeLa 48 h 65 
9h 16.6 ± 0.36 34.0 ± 3.3 HeLa 48 h 65 
9i 39.9 ± 1.76 34.0 ± 3.3 HeLa 48 h 65 
9j 15.0 ± 4.8 34.0 ± 3.3 HeLa 48 h 65 
9k 5.0 ± 0.4 34.0 ± 3.3 HeLa 48 h 65 
9l 3.6 ± 3.3 34.0 ± 3.3 HeLa 48 h 65 
11 3.0 ± 2.5 5.0 ± 2.5 MDA-MB-468 48 h 45 
12a 2.0 ± 1.5 5.0 ± 2.5 MDA-MB-468 48 h 45 
12b 3.0 ± 1.5 5.0 ± 2.5 MDA-MB-468 48 h 45 
12c 2.0 ± 2.5 5.0 ± 2.5 MDA-MB-468 48 h 45 
12d 3.0 ± 4.5 5.0 ± 2.5 MDA-MB-468 48 h 45 
12e 4.0 ± 6.5 5.0 ± 2.5 MDA-MB-468 48 h 45 
13 29.9 ± 6.1 9.1 ± 2.8 HeLa 48 h 51 
14 13.0 ± 2.8 9.1 ± 2.8 HeLa 48 h 45 
15 43 ± 2.2 22.1 ± 3.6 KB-3-1 48 h 27 
15 30.9 ± 1.1 10.5 ± 0.5 HepG2 48 h 27 
15 50.3 ± 0.2 11.6 ± 0.2 HeLa 48 h 27 
16 about 4 N/A U373 72 h 31 
16 about 4 N/A MCF-7 72 h 31 
19 78.2 ± 0.2 84 A2780/AD 24 h 29 
23c 6.6 ± 3.0 42 ± 7 (5-FdU) A549 48 h 35 
26d 27 ± 11 42 ± 7 (5-FdU) A549 48 h 50 
26e 46 ± 22 42 ± 7 (5-FdU) A549 48 h 50 
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28 3.4 ± 1.6 42 ± 7 (5-FdU) A549 48 h 50 
29 8.6 ± 0.2 2.7 ± 0.1 MCF-7 48 h 44 
29 16.9 ± 1.5 8.2 ± 1.5 U2OS 48 h 44 
29 29.8 ± 1.0 3.9 ± 1.0 HepG2 48 h 44 
30a 13.6 19.5 (Ara-C) HeLa N/A 22 
30b 11.9 19.5 (Ara-C) HeLa N/A 22 
30c 11.4 19.5 (Ara-C) HeLa N/A 22 
30d 8.6 19.5 (Ara-C) HeLa N/A 22 
30e 9.9 19.5 (Ara-C) HeLa N/A 22 
31a 6.4 19.5 (Ara-C) HeLa N/A 22 
31b 5.7 19.5 (Ara-C) HeLa N/A 22 
31c 6.5 19.5 (Ara-C) HeLa N/A 22 
32 7.8 19.5 (Ara-C) HeLa N/A 22 
33 5.2 51.2 (Ara-C) MCF-7 N/A 24 
34 3.4 51.2 (Ara-C) MCF-7 N/A 24 
35, 36 4-10 N/A MCF-7 72 h 26 
35, 36 4-10 N/A EVSA-T 72 h 26 
35, 36 4-10 N/A NB69 72 h 26 
35, 36 4-10 N/A H4 72 h 26 
35, 36 4-10 N/A ECV 72 h 26 
37c 7.3 ± 0.4 18 ± 1 MOLT-4 N/A 42 
37c 24 ± 4 71 ± 8 MCF-7 N/A 42 
38a 4.4 51.2 (Ara-C) MCF-7 N/A 23 
38b 2.6 51.2 (Ara-C) MCF-7 N/A 23 
38c 2.4 51.2 (Ara-C) MCF-7 N/A 23 
38d 2.6 51.2 (Ara-C) MCF-7 N/A 23 
39 1.0 51.2 (Ara-C) MCF-7 N/A 23 
40b 4.75 N/A MCF-7 N/A 38 
40b 75.1 N/A HeLa N/A 38 
17 9.3 ± 2.2 9.2 ± 0.6 HeLa  48 h 
300–400 nm 
2.6 J cm-2 
66 
18 17.3 ± 2.9 9.2 ± 0.6 HeLa  48 h 
300–400 nm 
2.6 J cm-2 
66 
47 18.3 ± 1.4 9.2 ± 0.6 HeLa  48 h 
300–400 nm 
2.6 J cm-2 
66 
48 5.4 ± 1.0 9.2 ± 0.6 HeLa  48 h 
300–400 nm 
2.6 J cm-2 
66 
48 13.6 ± 1.7 N/A PC-3  48 h 
300–400 nm 
2.6 J cm-2 
66 
49 0.9 ± 0.1 N/A HeLa  24 h 
590–700 nm  
46 
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a – cisplatin unless otherwise indicated (5-FdU – 5-fluorodeoxyuridine, Ara-C – cytarabine), N/A – not available. 
5 J cm-2 
50 3.3 ± 2.3 N/A HeLa 24 h 
590–700 nm  
5 J cm-2 
46 
51c 0.1 N/A HeLa 24 h 
>505 nm 
105.1 J cm-2 
43 
52 9.3 ± 0.8 9.2 ± 0.6 HeLa 48 h 
300–400 nm 
2.6 J cm-2 
47 
53 9.7 ± 4.4 9.2 ± 0.6 HeLa 48 h 
300–400 nm 
2.6 J cm-2 
47 
53 19.2 ± 2.4 74.8 ± 14.8 PC-3 48 h 
300–400 nm 
2.6 J cm-2 
47 
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Re(I) tricarbonyl complexes with N, N, N-tridentate ligands. The second type of Re 
organometallic complexes that yielded several cytotoxic compounds is Re(I) tricarbonyl 
complexes with a tridentate ligand coordinated to the Re center via three N atoms (Figure 2). 
Dipicolylamine (Dpa) and N, N-bisquinoline (BQ) based ligands have been initially used with 
the Re(CO)3 core for 99mTc/Re(I) studies and luminescent labeling. Specific targeting of the 
folate and cublin receptors overexpressed in certain types of cancer has been achieved by 
coupling the [ReBQ(CO)3]+ complexes 17 and 18 (Figure 2) to folate29 and vitamin B12,34 
respectively. The resulting Re bioconjugates 19 and 20 (Figure 2) were rapidly taken up via the 
corresponding receptor-mediated pathways. The specificity of 19 and 20 was controlled by 
comparing the uptake on receptor overexpressing cell lines (human adramycin and cisplatin-
resistant ovarian carcinoma A2780/AD for folate and human placental choriocarcinoma BeWo 
for B12) with that on a receptor-negative cell line (Chinese hamster ovary, CHO). In the case of 
the Re-folate conjugate 19, fluorescence microscopy imaging revealed a rapid internalization of 
19 by A2780/AD cells and a non-specific surface binding of 19 to CHO cells. Folate conjugation 
greatly increased the cytotoxicity of 17 from around 0.6 mM to 80 M.29 However, the non-
specific binding of 19 to CHO cells resulted into the same anti-proliferative effect as on a folate 
receptor-positive A2780/AD cell line. Of note, a DNA-mediated mode of action for the Re-folate 
conjugate 19 could be ruled out. The biological activity of 19 has been attributed to the intact 
complex since 48 h incubation of 19 in PBS (pH 7.4) with a 100-fold excess of histidine or 
glutathione did not result in any change in LC-MS chromatogram. Fluorescence microscopy 
showed that the Re-B12 conjugate 20, on the other hand, displayed no emission in CHO cells and 
a strong signal in BeWo cells.34 These results were reflected in the observed cytotoxicity of the 
Re-B12 conjugate that was more active against the cubilin-positive BeWo cell line. Yet, 
compound 20 only produced its anti-proliferative effect at high concentration (IC50 2 mM). 
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Figure 2. Cytotoxic Re(I) tricarbonyl complexes with bisquinoline-based ligands.  
Some of the most cytotoxic Re organometallic compounds have been prepared by 
conjugation of [Re(CO)3Dpa]+ and [ReBQ(CO)3]+  to thymidine and uridine at the C5’, C2’, N3 
and C5 positions with spacers of different lengths (28 on Figure 2 and 21–27 on Figure 3).35, 50 
The activity of complexes 21–28 varies greatly with the derivatization position and the length 
and nature of the spacer. In fact, C2’ (21) and C5 (22) were not active against A549 lung cancer 
cell line. Derivatization via positions C5’ (23–25) and N3 (26–28) proved to be the most 
advantageous in the view of cytotoxicity. However, the anti-proliferative effect of C5’ and N3 
derivatives strongly depended on the spacer used. While C5’ conjugates 24 and 25 and N3 
derivatives 27 have IC50 values in the mM range, compounds 23, 26 and 28 possess much higher 
cytotoxicity in M range. Elongation of the spacer and use of [ReBQ(CO)3]+ resulted into an 
increase in the cytotoxicity, reaching an IC50 value of about 3.5 M (28).50 Interestingly, while 
the above discussed folate and B12 conjugation allowed the complex to act via the corresponding 
receptors, thymidine-derivatized Re complexes were not taken up via the thymidine pathway 
and only weakly affected hTk-1, which is the primary enzyme involved in thymidine salvage 
pathway. The cellular localization of the [ReBQ(CO)3]+ bioconjugates vary considerably. While 
the Re-folate bioconjugate 19 seemed uniformly spread all over A2780/AD cells,29 the Re-B12 
conjugate 20 had a more pronounced emission in the nucleoli, besides cytoplasm.34 The 
thymidine derivative 28 was only observed outside the nucleus and co-localized with endosome 
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staining by fluorescence microscopy.50 While no exact 99mTc analogues of these complexes exist, 
several chemically robust 99mTc-labeled compounds have been prepared with dipicolylamine and 
N, N-bisquinoline ligands.67-71 One of such derivatives has been used to image transplanted 
neural stem and progenitor cells in a SPECT/CT study on mice.68  
As already discussed for Re bisimine compounds above, despite the favorable photophysical 
properties of certain Re organometallic complexes, emission microscopy localization is not 
always possible or accurate due to luminescence quenching. Complexes of type [ReBQ(CO)3]+ 
sometimes share the same problem. For instance, a [ReBQ(CO)3]+  complex with an azide group 
(29 on Figure 2) could not be localized by fluorescence microscopy in HeLa cells, although the 
cytotoxicity profile indicates that it is taken up by cells. In fact, 29 approaches the cytotoxicity 
of cisplatin on U2OS, HepG2 and MCF-7 (IC50 6–39 M, cisplatin 1–9 M).44 Although 29 
could not be imaged in cells by fluorescent microscopy, the major mode of action of this 
[ReBQ(CO)3]+ compound has been studied in detail using MCF-7 cells grown on a biosensor 
chip micro-bioreactor and isolated mitochondria. The complex had a strong effect on cellular 
metabolism by acting directly on mitochondria respiration. This activity was most likely due to 
the intact 29 as no decomposition was detected by LC-MS when 29 was incubated in human 
blood plasma for 72 h.  
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Figure 3. Cytotoxic Re(I) tricarbonyl complexes with dipicolylamine-based ligands. 
Alkoxo/hydroxo Re(I) carbonyl complexes. Re(I) alkoxo/hydroxo carbonyl complexes 
(Figure 4) were the first Re organometallic compounds that were shown to possess an anti-cancer 
activity.22, 24 Designed with the cisplatin ligand exchange-based mechanism of action in mind, 
this type of complexes has labile alkoxy/hydroxyl ligands. The dppf ligand of the Re compounds 
31 and 32 (Figure 4) can also be released/exchanged and contributes to the overall cytotoxic 
effect, as dppf has been reported to be toxic on its own.72, 73 Re(I) alkoxo/hydroxo compounds 
have been screened on over ten different human and murine tumor cell lines. These complexes 
were generally very active against suspended cancer cell cultures. However, on solid tumor cells, 
their cytotoxicity significantly varied with each particular cell line. The mechanism of toxicity 
has been described in considerable detail for compounds 30–31.22 The alkoxo/hydroxo Re(I) 
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carbonyl compounds are able to cause DNA strand scission and severely affect the nucleic acid 
metabolism via enzymes such as dihydrofolate reductase, PRPP-amido transferase and 
thymidine kinase.22 Similarly to 30–32, complexes 33 and 34 (Figure 4) are more cytotoxic 
towards suspended cancer cells than solid tumor cell lines.24 They, however, show improved 
activity on MCF-7 breast cancer. Their mechanism of action has not been studied, but their labile 
hydroxide and aminoethanol ligands are likely to be displaced in cells. 
 
Figure 4. Cytotoxic Re(I) alcoxo/hydroxo complexes. 
 
 
Re(I) tricarbonyl complexes with NO bidentate ligand. Two types of cytotoxic Re(I) 
carbonyl complexes coordinating a bidentate ligand via N and O atoms [Re(CO)3(N-O)X] (X 
=Cl, Br)  have been reported to date (Figure 5).26, 42 Various 5-nitrosopyrimidine Re complexes 
(35, 36) induced a non-negligible cell growth at low concentration (up to 2 M), but reduced 
cellular proliferation at higher concentration (IC50 4–10 M) on five human tumor cell lines 
(breast cancer MCF-7 and EVSA-T, neuroblastoma NB69, glioma H4 and bladder carcinoma 
ECV).26 Their mode of action was not explored, but enhanced cellular growth at lower 
concentration was explained in terms of the “heavy atom” effect on the estrogen receptor that 
has been previously described for Cd.74, 75  
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Semicarbazones were used as ligands in Re compounds 3742 since they are known to have 
their own pharmacological activity. The resulting complexes achieved cytotoxicity comparable 
to cisplatin towards acute lymphoblastic leukemia MOLT-4 cells (IC50 1–24 M, cisplatin 18 
M) and did not strongly affect healthy fibroblast cells (IC50 > 125 M). The activity was 
correlated with lipophilicity and was generally similar or higher compared to non-coordinated 
semicarbazone ligands. However, most Re semicarbazone complexes displayed very low 
toxicity toward the MCF-7 cells. The “hit” Re semicarbazone compound 37c that combined 
strong cytotoxicity (7.3 and 24 M) against both MOLT-4 and MCF-7 cancer cell lines with low 
toxicity towards healthy fibroblasts might have actually inherited its properties from the free 
ligand that has very similar IC50 values. Interestingly, NMR studies in DMSO showed that 37c 
had a more acid phenolic proton than the corresponding ligand and tended to dimerize via loss 
of Br ligands. The authors judged dimerization in cell unlikely due to low concentrations, but 
hypothesized that good donor groups from biomolecules could easily substitute the Br ligand. 
 
 
Figure 5. Cytotoxic Re(I) tricarbonyl complexes with N-O bidentate ligand. 
 
Re(I) tricarbonyl complexes with P-P and Se-Se bidentate ligands. Tricarbonyl Re(I) 
bidentate phosphine complexes [Re(CO)3(P-P)Br] 38 and 39 (Figure 6) have also been among 
the first Re organometallic compounds screened for cytotoxicity.23 Tested on over 10 various 
cancer cell lines, these compounds were found to have IC50 values of about 5–10 M, showing 
particular activity against MCF-7 breast cancer and HeLa-S3 suspended uterine carcinoma. More 
recently, Re(I)  tricarbonyl complexes with diseleno ligands Re(CO)3(Se-Se)Cl (40, 41 on Figure 
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6) have been tested on HT 29 (colorectal cancer), MCF-7 (hormone-dependent breast cancer), 
A549S (lung adenocarcinoma) and HeLa (solid uterine carcinoma).38 Curiously, these 
compounds also possessed a particularly high activity (4 M) against MCF-7 breast cancer cells, 
while being only moderately or essentially non-toxic to other cell lines. This property has been 
further explored in the course of an in vivo study on MCF-7 tumor bearing mice.41 In this work, 
the treatment with Re organometallic complex 40b was combined with cisplatin and Gd(III) 
administration, since both inorganic Re/cisplatin and Gd/cisplatin co-administration studies had 
previously shown synergetic action between cisplatin/Re and cisplatin/Gd(III) compounds, 
respectively. The intraperitoneal cisplatin administration (2 per week, 3 mg/kg) combined with 
oral daily (5/7 days/week) administration of a Gd complex ((tetrakis(1-octanol) tris(5-
aminosalicylate) Gd(III)) and Re(CO)3(Se-Se)Cl (40b) led to 50% tumor volume reduction after 
3 weeks treatment. By comparison, only 25% tumor volume reduction was observed for mice 
treated with cisplatin only. However, no control groups were treated with Re or Gd compound 
only, so the extent of complex 40b contribution to tumor reduction has not been directly 
assessed. The largest effect on tumor volume was achieved using the maxim dose of Gd (100 
mg/kg) and the minimal dose of Re (10 mg/kg). In the mice treated with higher doses of Re, 
more deaths were observed.   
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Figure 6. Cytotoxic Re(I) tricarbonyl complexes with P-P and Se-Se bidentate ligands. 
 
Re-containing enzyme and receptor inhibitors. While a couple of cytotoxic Re complex 
discussed above might act via enzyme/receptor inhibition, none of them have been initially 
intended as such. In contrast, certain Re organometallic compounds, cyclopentadienyl (Cp) Re 
complexes in particular, have been purposely designed to bind a particular enzyme or receptor.25, 
76, 77 Specific interaction between Re complexes and their biological targets has been achieved 
by incorporating a Re(CO)3 core into a known organic enzyme inhibitor or receptor ligand. The 
earliest examples of such Re compounds with anti-proliferative activity are Jaouen’s Re-
Tamoxifen (42, Figure 7) derivatives where a phenyl group is replaced by a Cp ring of 
[Re(CO)3Cp].25 Tamoxifen inhibits the estrogen receptor (ER) and is used for the treatment of 
hormone-responsive breast tumors. The derivatization with Re slightly decreased the affinity of 
Tamoxifen for ER. However, cytotoxicity assays on MCF-7 ER(+) breast cancer cells showed 
that Re-Tamoxifen conjugates were even slightly more active than Tamoxifen by itself. A small 
effect (about 10% reduction in cell viability at 1 M) was also observed on Tamoxifen-resistant 
MDA-MB231 breast cancer cell line. In vivo distribution study in rats has been realized with a 
related compound where 99mTc(CO)3Cp moiety was conjugated to atriaryl butane skeleton of 
tamoxifen via an amide bond.78 
Recently, the Re(CO)3 core has been conjugated to sulfonamide moieties to target human 
carbonic anhydrases (hCAs), which have emerged as an interesting target for therapy and 
diagnosis due to their overexpression induced by hypoxia in cancer cells.79-81 High concentration 
of carbonic acid resulting from this excessive activity of hCAs leads to a pronounced decrease 
in extracellular pH (down to ca. 6 instead of 7.4).76, 79 Re complexes (43–46, Figure 7) have been 
shown to be excellent hCA inhibitors with submicromolar affinities and interesting selectivity 
profiles for various hCA isoforms.76, 82 No IC50 values were reported, but efficient inhibition of 
hCA in HeLa and HT29 cells has been demonstrated by monitoring the rise in extracellular pH 
upon incubation with Re inhibitors. The X-ray structure has shown that Re hCA inhibitors bound 
to the enzyme in a similar manner as organic inhibitors and the Re core only participated in 
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hydrophobic interactions with Phe, Leu and Pro amino acid residues. 99mTc analogues of 
compounds 46a and b have also been synthesized in an excellent yield,82 while the 99mTc version 
of inhibitor 43 has been already tested on xenograft mice with CAIX expressing tumors.76 
However, these in vivo biodistribution studies have shown that, despite excellent in vitro results, 
Re complex 43 failed to significantly accumulate in tumors.  
 
 
Figure 7. Re organometallic enzyme and receptor inhibitors. 
 
PHOTO-TOXIC Re ORGANOMETALLIC COMPLEXES 
Very few photo-toxic Re organometallic compounds have been identified to date (Figure 8).43, 
44, 46, 47 Most of them act as photodynamic therapy (PDT) photosensitizers (PS) – i.e. they transfer 
the energy received from light to oxygen (present in tissues) to generate reactive oxygen species 
(ROS). A PS excited by irradiation undergoes two types of reactions.83 In the so-called type I 
reaction, the PS directly interacts with a substrate (e.g. cell membrane, protein) to form radicals 
or radical ions, which can in turn interact with oxygen to produce the highly reactive singlet 
oxygen. The type II reaction is defined as generation of singlet oxygen via PS-oxygen 
interaction.83 Although many more Re compounds have been identified as efficient triplet 
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photosensitizers,39, 84-88 this property has been more applied in photo-catalysis than in anti-cancer 
drug development.  
The Re(I) tricarbonyl N,N-bisquinoline complexes [ReBQ(CO)3]+ 17 and 18 already 
discussed above are capable of producing singlet oxygen when irradiated at 355 nm.44, 47 Singlet 
oxygen generation of these Re complexes decreases with solvent polarity and therefore depends 
on their cellular localization. UV-A irradiation of the essentially non-toxic Re(I) tricarbonyl 
N,N-bisquinoline complexes 17 and 18 used in folate29 and B1234 conjugation studies has revealed 
that the anti-proliferative activity of these compounds on HeLa cells could be increased by a 10-
fold to 9.3 and 17.3 M (HeLa) respectively by using a relatively low light dose (2.6 J/cm2).44 
This success, however, could not be reproduced on PC-3 cell line47 without conjugation of the 
Re complex to a bombesin derivative (48 on Figure 8) to target the GRP receptors overexpressed 
in certain types of cancer (5.4 μM on HeLa and 13.6 μM on PC-3).44, 47 Addition of a nuclear 
localization signal peptide (NLS) (47 on Figure 8) led to a strong increase of the dark cytotoxicity 
(35.1 M HeLa). This could be the result of change in cellular localization upon NLS 
conjugation from cytoplasm to nucleoli, as observed by fluorescent microscopy. The bombesin 
derivative 48 could not be visualized on HeLa cells due to luminescence quenching.  
Some photosensitizing porphyrin-Re conjugates (49, 50 on Figure 8) have been recently 
shown to greatly increase their cytotoxicity (from >100 M to 3 M IC50) upon 590–700 nm 
light irradiation.46 However, the light activity of these compounds originated entirely from the 
porphyrin moiety as the Re complex present in the conjugate does not produce any singlet 
oxygen upon irradiation at 590–700 nm. The Re conjugation, however, was found to improve 
the uptake of these porphyrin-Re conjugates. Hot 99mTc analogues of 49 and 50 have also been 
prepared and shown to be stable in cell culture medium for at least 24 h by HPLC studies.89 
Re organometallic compounds can also function as photosensitizers in the visible light range 
as recently demonstrated with Re(I) tricarbonyl indolato complexes (51).43 These compounds’ 
UV/vis absorption extends up to 600 nm so that visible light irradiation (>505 nm) results into 
up to a 1000 fold increase in anti-cancer activity on HeLa cells and the most active of them 
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significantly reduced the size of melanoma spheroids. Singlet oxygen formation was detected 
for all complexes of the study by indirect para-nitrosodimethylaniline/imidazole assay90 The 
most cytotoxic complex 51c (0.1 M HeLa) was studied in more detail. Curiously, it underwent 
pyridine ligand substitution after irradiation in presence of 4-dimethyaminopyridine. 
Considerable ROS production was also detected in vitro after irradiation. Fluorescence and 
phase-contrast microscopy revealed that this complex was localizing in the cellular membrane 
and induced severe morphological changes in HeLa cells upon irradiation. In fact, addition of a 
membrane-localized anti-oxidant protected the cells from the anti-proliferative effect of the Re 
complex.  
 
	 23
 
Figure 8. Photo-toxic Re organometallic compounds. 
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Recently, our group has incorporated a UVA (355 nm) photo-labile protecting group (PLPG) 
into the Re(I) N,N-bisquinoline bioconjugates 47 and 48 described above.47 Upon irradiation at 
a very low light dose (1.2 J/cm2), the resulting photo-caged bioconjugates 52 and 53 (Scheme 1) 
liberated the Re complex 17 in addition to singlet oxygen generation. IC50 values of c.a. 9 M 
were thus reached. Biological studies demonstrated that the most cytotoxic compound 52 
accumulated considerably in nucleoli where it could affect both DNA and RNA triggered cell 
death via both apoptosis and necrosis. 
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Scheme 1. Photo-caged Re organometallic compounds. 
 
CONCLUSIONS AND PERSPECTIVES 
In this review, we have summarized the currently known Re organometallic compounds with 
anti-cancer activity, as well as highlighted their modes of cytotoxic action when possible. The 
majority of anti-proliferative Re organometallic complexes act as “traditional” chemotherapeutic 
agents, although a few photo-active Re complexes have also been recently reported. Potentially, 
an even larger number of Re organometallic compounds with PDT activity could be identified 
by screening the singlet oxygen production of known Re photocatalysts.  
Most of the compounds presented in this review are potent anti-cancer agents with IC50 values 
reaching or exceeding the activity of cisplatin. The underlying mechanisms of toxicity are, 
however, not always fully elucidated and, to the best of our knowledge, only one in vivo study 
has been conducted on cold Re organometallic complexes.41 This study as well as a couple of 
successful in vivo evaluations of coordinative Re compounds91, 92 have demonstrated a 
synergistic action of Re compounds with cisplatin. Undoubtedly, more thorough biological 
investigations both in vitro and in vivo would give us a better understanding of the cytotoxicity 
of Re organometallic complexes. In this context, preparation of “hot” analogues of promising 
Re compounds to visualize their in vivo behavior is an indispensable step and the most helpful 
tool to allow for the development of powerful and selective anti-cancer drugs.  
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